Loading company…
Spiro Medical develops neuromodulation technology for respiratory conditions including asthma and COPD.
Founded in 2023 and based in Belleair Bluffs, US, Spiro Medical develops treatments for asthma, chronic cough and COPD. Its Spiro Neuromodulation System is designed to alter neural pathways involved in respiratory function. The company serves hospitals and specialty clinics in North America and Europe. In January 2026, it raised USD 67.00 million in Series A funding led by Andera Partners and Omega Funds, among others.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in